New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
The Stanford Health Care Center for Memory Disorders is encouraged that there is a new treatment option for certain patients with Alzheimer’s disease. On January 6, 2023, the FDA granted accelerated approval for lecanemab (LeqembiTM).
Treatment Options for Alzheimer's Disease
Specific treatment for Alzheimer's disease will be determined by your physician based on:
- Your age, overall health, and medical history
- Extent of the disease
- Your tolerance for specific medications, procedures, or therapies
- Expectations for the course of the disease
- Your opinion or preference
At this time, there is no cure for Alzheimer's and no treatment available to reverse the deterioration of Alzheimer's disease. New research findings give reason for hope, and several drugs are being studied in clinical trials to determine if they can slow the progress of the disease or improve memory for a period of time.
There are some medications available to assist in managing some of the most troubling symptoms of Alzheimer's disease, including the following:
- Behavioral disturbance
The FDA has approved two therapies that may help slow the progression of Alzheimer's, aducanumab and lecanemab.
In managing the disease, physical exercise and social activity are important, as are proper nutrition, health maintenance, and a calm and well-structured environment.
Open trials refer to studies currently recruiting participants or that may recruit participants in the near future. Closed trials are not currently enrolling, but similar studies may open in the future.
See a Stanford specialist to learn about your treatment options. Visit one of our clinics to make an appointment.
Stanford, CA 94305
Palo Alto, CA 94304
Palo Alto, CA 94304